Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-3.29% $2.06
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 49.85 mill |
EPS: | -5.44 |
P/E: | -0.380 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 24.20 mill |
Avg Daily Volume: | 0.0764 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.380 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.06x |
Company: PE -0.380 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$3.90 (89.15%) $1.837 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 1.940 - 2.18 ( +/- 5.83%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-02 | Robinson James A. Jr. | Buy | 150 437 | Stock Option (Right to Buy) |
2023-10-02 | Kirk Allan | Buy | 150 437 | Stock Option (Right to Buy) |
2023-10-01 | Robinson James A. Jr. | Buy | 0 | |
2023-10-02 | Kirk Allan | Buy | 0 | |
2023-05-05 | Bvf Partners L P/il | Buy | 3 084 090 | Warrants to Purchase Common Stock |
INSIDER POWER |
---|
100.00 |
Last 95 transactions |
Buy: 17 704 764 | Sell: 1 858 032 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $2.06 (-3.29% ) |
Volume | 0.0414 mill |
Avg. Vol. | 0.0764 mill |
% of Avg. Vol | 54.20 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.